Feasibility and Colorectal Benefits of Pulses Supplementation
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Sep 7, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of beans, a nutritious food often overlooked in our diets, on people who have colorectal polyps (small growths in the colon) and are overweight or obese. The researchers want to see if adding beans to the diet can improve bowel health and help prevent colon cancer in the future. They believe that understanding how beans affect our health could lead to better dietary recommendations for everyone.
To participate in this study, you need to be between 30 and 80 years old and have a body mass index (BMI) of 25 or higher, which means you are considered overweight or obese. You also need to be scheduled for a routine colonoscopy, a procedure used to screen for colon cancer. However, some people may not be eligible, such as those who have certain medical conditions, are pregnant, or have had any cancer in the past 10 years. If you join the study, you can expect to learn more about your health while contributing to important research that could benefit others in the future.
Gender
ALL
Eligibility criteria
- Inclusions:
- • 1. 30-80 years-old
- • 2. Overweight or obesity (body mass index ≥ 25 kg/m2)
- • 3. Planned for a standard of care colonoscopy for colon cancer screening
- Exclusions:
- • 1. Intolerance to a bean or high bean consumer based on a screening survey
- • 2. Pregnancy or actively planning to get pregnant
- • 3. Any active gastrointestinal disease resulting in disturbed gut function or malabsorption (e.g., chronic diarrhea or inflammatory bowel disease)
- • 4. Current or history of any malignancy in the past 10 years.
- • 5. Chronic use of opioids, anti-inflammatory drugs, antibiotics, prebiotics, or probiotics within 1 month of study endpoints
- • 6. History of a significant systemic condition (e.g., heart disease, chronic kidney disease, liver dysfunction or immune suppression), or abnormal laboratory markers (e.g., abnormal liver enzymes, creatinine, clotting factors, or low platelets count). The severity of the intolerance to fiber/ the medical conditions/lab markers and eligibility will be defined after the careful interview of the patient/review of the medical records by Dr. Hussan)
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Patients applied
Trial Officials
Hisham Hussan, MD
Principal Investigator
UC Davis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported